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Abstract
Background: Several clinical trials and recent meta-analyses have demonstrated that administration of recombinant
human granulocyte-colony stimulating factor (G-CSF) is safe and, only in patients with large acute myocardial
infarction (AMI), is associated with an improvement in left ventricular ejection fraction. Moreover, the mobilization and
engraftment of the bone marrow-derived cells may differ significantly among patients, interfering with the restoration
of left ventricular function after treatment. Therefore, the clinical potential application of the G-CSF has not yet been
fully elucidated.
Methods/Design: The RIGENERA 2.0 trial is a multicenter, phase II, placebo-controlled, randomized, open-label,
with blinded evaluation of endpoints (PROBE) trial in which 120 patients with an acute ST-elevation myocardial
infarction (STEMI) undergoing successful revascularization but with residual myocardial dysfunction will be enrolled.
In cases where there is a left ventricular ejection fraction (LVEF) ≤45 % the patient will be electronically randomized
(1:1 ratio) to receive either subcutaneous recombinant human G-CSF (group 1) or placebo (group 2) both added on
top of optimal standard of care. Both groups will undergo myocardial contrast echocardiography with intravenous
infusion of sulfur hexafluoride (MCE) whilst undergoing the echocardiogram.
The primary efficacy endpoint is the evaluation of the LVEF at 6 months after AMI assessed by cardiac magnetic
resonance. Secondary efficacy endpoints are the evaluation of LVEF at 6 months after AMI assessed by echocardiography,
left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) assessed by cardiac
magnetic resonance and echocardiography at 6 months, together with the incidence of major adverse clinical
events (MACE) defined as death, myocardial infarction, sustained cardiac arrhythmias, cardiogenic shock, stroke
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and re-hospitalization due to heart failure at 1 year.
Discussion: The RIGENERA 2.0 trial will test whether G-CSF administration and MCE, through the enhancement of
the bone marrow-derived cells homing in the myocardium, determines an improvement in regional and global
contractile function, myocardial perfusion and infarct extension in patients with large AMI. The results of the
present study are expected to envision routine clinical use of this safe, affordable and reproducible approach in
patients with successful revascularization after AMI.
Trial registration: ClinicalTrials.gov: NCT02502747 (29 June 2015); EudraCT: 2015-002189-21 (10 July 2015).
Keywords: ST-elevation myocardial infarction (STEMI), Granulocyte-colony stimulating factor (G-CSF), Bone
marrow-derived stem cells, Myocardial contrast echocardiography (MCE), Remodeling, Post-myocardial infarction
heart failure
Background
The long-term prognosis of patients suffering from
acute myocardial infarction (AMI) has progressively
improved since the introduction of reperfusion therap-
ies and, in particular, of primary angioplasty [1]. In the
setting of ST-elevation myocardial infarction (STEMI),
the immediate reopening of acutely occluded coronary
arteries via primary angioplasty is the treatment of
choice to salvage the ischemic myocardium. However,
the sudden re-initiation of blood flow can lead to a
local acute inflammatory response with further endo-
thelial and myocardial damage. This phenomenon,
described as “reperfusion injury”, may explain why, des-
pite optimum myocardial reperfusion, the short-term
mortality after AMI approaches 7 % [1] and the long-term
incidence of heart failure in reported to be between 15
and 20 % [2, 3]. Despite the use of full conventional
treatments, including ACE inhibitors, beta-blockers, al-
dosterone inhibitors and diuretics, in the context of
randomized controlled trials, yearly mortality rates of
patients with post-infarction heart failure are still 10 %
and re-hospitalization for worsening of heart failure oc-
curs at a yearly rate of 6–8 % [4].
A major reason for the high morbidity and mortality
is that the heart has an inadequate regenerative re-
sponse to the myocardial necrosis following AMI; cell
death from the ischemic damage can lead to progres-
sive ventricular dilation and dysfunction (i.e., adverse
left ventricular remodeling). Numerous pre-clinical
studies and small to intermediate size clinical trials
have demonstrated beneficial effects of bone marrow-
derived cells on top of state-of-the-art reperfusion
treatment providing compelling evidence that bone
marrow- derived cells do contribute to cardiac repair
after acute myocardial injury, limiting infarct expansion
and improving cardiac function, most likely via para-
crine mechanisms [5–7].
Considering that recovery of post-infarction left
ventricular function is favorably correlated with bone
marrow-derived stem cell mobilization induced by
endogenous granulocyte-colony stimulating factor
(G-CSF) [8, 9], therapeutic stem cell mobilization
has been proposed as a therapeutic tool. Several basic
studies have supported this notion suggesting that stem
cell mobilization might improve left ventricular function
by increasing stem cell homing in the heart in addition to
a favorable direct effect of G-CSF on the injured myocar-
dium [10–12].
However, the clinical effects of G-CSF on patients with
AMI have so far shown mixed results [13]: G-CSF was
proven to be safe but the therapeutic effect appeared
modest. Nevertheless, in patients with large myocardial
infarction the effect was clinically relevant, approaching
a 5 % increase in left ventricular ejection fraction
(LVEF). In particular, in the RIGENERA trial conducted
by our group, 41 patients with large anterior wall AMI
at high risk of unfavorable remodeling were randomized
1:2 to Lenograstim (recombinant human (rhu) G-CSF,
Myelostim 34, Italfarmaco, Milan, Italy) (10 μg/kg/day
for 5 days) or to conventional therapy. After a median
follow-up of 5 months the patients treated with Leno-
grastim exhibited improvement of 5 % in LVEF, in the
absence of left ventricular dilation. In contrast, the
patients treated conventionally exhibited significant dila-
tion in the absence of an improvement in LVEF [14].
Moreover, a subgroup of eight patients randomized to
Lenograstim were administered a second-generation
ultrasound contrast agent containing sulfur hexafluoride
(SonoVue®, Bracco, Milan, Italy) administered intraven-
ously (5 ml at 1 ml/min) to achieve myocardial opa-
cification in order to collect diagnostic images by
myocardial contrast echocardiography. Interestingly, a
post hoc analysis, revealed that patients receiving
SonoVue® showed a significant benefit in left ventricu-
lar function (unpublished data): the myocardial destruc-
tion of contrast medium-microbubbles by 3.5-MHz
ultrasound produced by the echo machine may have
increased the homing of the mobilized bone marrow-
derived stem cells. Additionally, two studies on animal
models have consistently demonstrated that the highly
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focused ultrasound-mediated stimulation of microbubbles
increased the migration of stem cells across the myocar-
dial endothelium into the post-ischemic myocardium in
vivo [15, 16].
In our study population, the long-term (10 years)
follow-up data, recently collected, confirmed the safety
of the protocol and, remarkably, patients treated with
G-CSF showed a significant improvement of the quality of
life assessed by New York Heart Association (NYHA)
functional class, Seattle Heart Failure Model, Minnesota
Living with Heart Failure Questionnaire (p < 0.005)
(unpublished data).
Therefore, on the basis of the previous results
collected by our group, the RIGENERA 2.0 trial
(ClinicalTrials.gov Identifier: NCT02502747; EudraCT
number: 2015-002189-21) was designed to specifically
test the efficacy of the combined effect of subcutaneous
G-CSF and sulfur hexafluoride on post-infarction left ven-
tricular function in patients with STEMI.
Methods
Study objectives
The overall objectives of the RIGENERA 2.0 trial are to
determine whether, in patients with large AMI undergoing
primary or rescue angioplasty, the administration of
subcutaneous Lenograstim (rhu G-CSF, Myelostim 34,
Italfarmaco, Milan, Italy) associated with myocardial
contrast echocardiography and the intravenous infu-
sion of sulfur hexafluoride (SonoVue®, Bracco, Milan,
Italy) determines an improvement in regional and global
contractile function, myocardial perfusion and infarct size
and is associated to a better quality of life.
Specifically, the primary efficacy endpoint is:
 LVEF at 6 months assessed by cardiac magnetic
resonance and centrally reviewed.
Secondary efficacy endpoints are:
 Left ventricular end-diastolic volume (LVEDV)
assessed by cardiac magnetic resonance at 6 months
and centrally reviewed
 Left ventricular end-systolic volume (LVESV) assessed
by cardiac magnetic resonance at 6 months and
centrally reviewed
 Left ventricular ejection fraction (LVEF) assessed by
2D echocardiography at 6 months and centrally
reviewed
 Left ventricular end-diastolic volume (LVEDV)
assessed by 2D echocardiography at 6 months and
centrally reviewed
 Left ventricular end-systolic volume (LVESV)
assessed by 2D echocardiography at 6 months
and centrally reviewed
 Incidence of major adverse clinical events (death,
myocardial infarction, sustained cardiac arrhythmias,
cardiogenic shock, stroke and re-hospitalization due
to heart failure at 1 year) (see Additional file 1)
Safety endpoints are:
 Incidence of adverse events
 Incidence of new neoplastic and hematological diseases.
Study design (Fig. 1)
The RIGENERA 2.0 trial is a phase II placebo-
controlled, randomized, open-label, with blinded evalu-
ation of endpoints (PROBE) trial. One hundred and
twenty STEMI patients are planned to be enrolled in
four Italian centers (Catholic University of the Sacred
Heart in Rome, University of Ferrara, Pisa and Padua).
Patients with an acute STEMI, as defined by the univer-
sal definition of AMI, undergoing acute revascularization
(i.e., either acute percutaneous coronary intervention
(PCI) within 24 hours of symptom onset or thrombolysis
within 12 hours followed by acute PCI within 24 hours
of symptom onset) will be screened at investigational
sites. Patients who have had acute PCI in institutions
different from the investigational sites (recruiting
centers) can also be included: interested patients may be
referred for screening to any of the participating study
sites within 3 to 4 days. Every patient will be informed
in person and receive the patient information letter and
informed consent form; as this trial has not yet begun
the recruitment phase, no informed consent form has
been provided to any patient; however, informed consent
will be obtained from all participants.
The study was approved by the ethical committee
(Comitato Etico del Policlinico Gemelli, Roma) and
AIFA (Italian Medicines Agency) in July 2015. The trial
will be conducted in accordance with the Italian Medical
Drug Law (received the AIFA approval in July 2015) and
the Good Clinical Practice guidelines. The RIGENERA
2.0 trial is an investigator-initiated trial and funded by
the Italian Ministry of Education and Research (PRIN
2010/2011/2010S7CET4).
Informed consent and assessment of eligibility of pa-
tients with respect to inclusion and exclusion criteria
will be done at the recruiting centers.
Inclusion criteria are:
1. Signed and dated informed consent
2. Men and women of any ethnic origin aged 18 years
or older
3. Patients with acute STEMI as defined by the
universal definition of AMI
4. Successful acute reperfusion therapy (residual
stenosis visually <50 % and thrombolysis in
Leone et al. Trials  (2016) 17:97 Page 3 of 8
myocardial infarction (TIMI) flow ≥2) within
24 hours of symptom onset or thrombolysis within
12 hours of symptom onset followed by successful
PCI within 24 hours after thrombolysis
5. LVEF ≤45 % with significant regional wall motion
abnormality assessed by quantitative
echocardiography 3 to 6 days after reperfusion
therapy
Exclusion criteria are:
1. Participation in another clinical trial within 30 days
prior to randomization
2. Pregnant or nursing women or women in
childbearing age not able to exclude the possibility
of a pregnancy
3. Mental condition rendering the patient unable to
understand the nature, scope and possible
consequences of the study or to follow the
protocol
4. Necessity to revascularize additional vessels,
outside the target coronary artery, after
investigational therapy/placebo administration
(additional revascularizations after primary PCI and
before investigational therapy/placebo administration
are allowed)
Fig. 1 Flow chart of the RIGENERA 2.0 trial. MCE myocardial contrast echocardiography
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5. Persistent cardiogenic shock
6. Known hematological and neoplastic diseases
7. Severe impaired renal function, i.e., eGFR <30 ml/min.
8. Persistent fever or diarrhea not responsive to
treatment within 4 weeks prior to screening or
severe infection
9. Uncontrolled hypertension (systolic >180 mmHg
and diastolic >120 mmHg).
10. Life expectancy of less than 2 years from any
non-cardiac cause or neoplastic disease
After ensuring that a patient meets all other eligibil-
ity criteria, the investigators will perform the echocar-
diography, an electronic record of which will be kept
and transferred to the central Echocardiography Core
Laboratory following analysis. After local quantifica-
tion of LVEF, randomization will be allowed for all
patients with LVEF ≤45 %. As soon as possible after
the enrollment the first cardiac magnetic resonance
will be performed. At randomization, every patient
will receive a number that will be used as the key
identifier for the entire study period.
Patients will be randomized to investigational therapy
or placebo according to a 1:1 ratio:
 Group 1: placebo on top of optimal standard of
care (LVEF will be evaluated by echocontrastography
with the infusion of sulfur hexafluoride:
SonoVue®, Bracco Milan, Italy) (see protocol in
Additional file 1)
 Group 2: administration of subcutaneous
Lenograstim (rhu G-CSF, Myelostim 34, Italfarmaco,
Milan, Italy) 5 to 10 days after successful reperfusion
of the culprit vessel of a large AMI, on top of
optimal standard of care (LVEF will be evaluated by
echocontrastography with the infusion of sulfur
hexafluoride: SonoVue®, Bracco, Milan, Italy)
(see protocol in Additional file 1)
Patients with a LVEF >45 % will not be randomized,
but will be classified as screening failures. Patients
randomized but not treated will be replaced. Patients
who discontinue the study after treatment, will not be
replaced.
Both in patients treated with Lenograstim and in
patients treated with placebo, immediately before the
first dose of Lenograstim or placebo and in the morning
of the last day of treatment in which the peak of bone
marrow-derived stem cell mobilization is expected, an
echocardiogram using an echocardiographic contrast
agent will be performed. On the days of administration
of the drug or placebo, electrocardiogram (ECG), blood
pressure, blood count and coagulation analyses will be
monitored (see Additional file 1).
In cases of muscle and bone pain or severe headache,
patients will be treated with paracetamol.
In the case of leukocytosis (>40,000/mcl) the dose of
G-CSF in 24 hours will be halved, and in the case of
leukocytosis (>70,000/mcl) completely stopped.
After hospital discharge, all study patients will return
to the clinical center for a follow-up visit after 30 days.
Six months after randomization all the patients will
undergo outpatient cardiac magnetic resonance and con-
ventional echocardiography. At 1 year all patients will
attend a final site visit at the clinical centers collecting
any clinical event. However, all clinical endpoints will be
reported as occurring throughout the follow-up. Major
adverse cardio-cerebrovascular events (death, myocardial
infarction, stroke and re-hospitalization due to heart
failure) at 1 year will be adjudicated by a clinical
event committee blinded to the patient treatment al-
location. This will ensure a consistent and unbiased
adjudication of events across all investigational sites.
Cardiac magnetic resonance
In the patients enrolled in the study, two different
contrast-cardiac magnetic resonance examinations will be
performed: the first as soon as possible after the enroll-
ment, the second 6 months after the randomization.
Moreover, the patients with severe renal disease will be
excluded (glomerular filtration rate <30 ml/min). Cardiac
magnetic resonance will be performed on a 1.5-T clinical
scanner (1.5 Tesla Magnetom Avanto, Siemens Medical
Solutions, Erlangen, Germany) using a phased-array
cardiac receiver coil. Additionally, ECG-gated breath-
hold cine imaging will be performed.
The cardiac magnetic resonance protocol includes:
1. Morphological and cine evaluation: to determine left
ventricular function, using a segmented steady-state
free-precession pulse sequence (TrueFISP) in multiple
short-axis views every 8 mm by encompassing the
left ventricle from base to apex. Typical in-plane
resolution is 1.7 × 1.2 × 8 mm; slice thickness:
6 mm; gap: 2 mm. Long-axis view, comparable
with standard echo images (two-chamber view,
three-chamber view and four-chamber view) will
be acquired
2. Myocardial edema evaluation: presence and location
of myocardial edema, including intramyocardial
hemorrhage will be evaluated on T2-weighted
images short-TI inversion-recovery fast spin echo
pulse, on consecutive short-axis views. The typical
parameters are reported: FOV: 380 to 400 mm;
TR: 2 R-R intervals; TE: 100 ms; TI: 150 ms;
matrix: 256 × 192; slice thickness: 8 mm
3. Perfusion at rest evaluation: rest first-pass myocardial
perfusion will be performed during administration of
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a gadolinium-based contrast agent (Multihance,
0.2 mmol/kg, Bracco, Milan, Italy) using single-shot
saturation recovery gradient-echo pulse sequence,
turbo-FLASH sequences. Three short-axis slices will
be obtained per heartbeat, every 10 mm, covering the
infarct area as seen during cine imaging (TR: 2.1 ms;
TE: 1.1 ms; flip angle 12°; time resolution: 1 s; voxel:
2.8 × 2.4 × 10 mm)
4. Early enhancement evaluation: after gadolinium
injection, the presence of microvascular damage will
be evaluated by T1-weighted 3D inversion recovery
gradient-echo sequences. The typical parameters are
reported: TR: 4.5 ms; TE: 1.3 ms; flip angle: 158°;
slice thickness: 8 mm; gap: 2 mm; matrix: 128 × 256;
field of view: 350 mm; pixel size: 1.4 mm/1.4 mm.
The images will be acquired on the same slice
position used for cine images. The presence of an
“early enhancement” will be performed after 2–5
minutes after contrast injection
5. Delayed enhancement evaluation: the presence of
myocardial necrosis detected by delayed contrast
deposition (“late gadolinium enhancement”) will be
evaluated with the same sequences on point 4, but
acquired 10–15 minutes after contrast injection. The
inversion time will be individually adapted to
suppress the remote myocardium signal (typical
range from 200 to 300 ms)
After acquisition protocol, the images will be analyzed
off-line using a dedicated workstation with a dedicated
post-processing software (Circle cvi42). The following
parameters will be obtained for each of two CMR
acquisitions:
 Analysis of steady-state free-precision sequences:
on all short-axis cine slices, the endocardial and
epicardial borders will be outlined manually on
end-diastolic and end-systolic images. LVEF,
end-diastolic and end-systolic volumes, and left
ventricular mass will be calculated from the
short-axis views
 Analysis of T2-weighted sequences: on T2-weighted
images, infarct-related edema was considered
present when the signal intensity of the myocardium
was >2 standard deviations of the mean signal
intensity of the controlateral remote region. The
total amount of myocardial edema, representing
area at risk, will be expressed as grams and as
percentage related to total myocardial mass
 Evaluation of Turbo-FLASH sequences: perfusion
defects on “first pass” will be evaluated for each
segment according with the 17-segments model
 Delayed enhancement analysis: on delayed
enhancement imaging, myocardial infarction will
be considered present if the signal intensity of
hyperenhanced myocardium is >5 standard
deviations of the mean signal intensity of the
remote region, and microvascular damage will be
defined as a hypoenhanced region within infarcted
myocardium. The total amount of myocardial
necrosis will be expressed as grams and also as
percentage related to total myocardial mass.
Moreover, a score will be used to define the
extent of necrosis for each segment according
with 17-segments model: 1 = necrosis between 0
and 25 % of the entire segment; 2 = necrosis
between 25 % and 50 % of the entire segment;
3 = necrosis between 50 % and 75 % of the entire
segment; 4 = transmural necrosis extending > 75 %
of the entire segment. Finally the amount of
salvaged myocardium, expressed as the difference
between area at risk on T2-weighted images and
extent of delayed enhancement, will be defined.
Echocardiography
The echocardiographic evaluation will be performed in
accordance with the recommendations of the American
Society of Echocardiography. The following views
should be evaluated during each echo evaluation: para-
sternal short-axis view, parasternal long-axis view,
apical four-chamber view, apical two-chamber view,
apical three-chamber view. Quantitative analyses in-
clude measurements of left ventricular dimensions: left
ventricle end-diastolic/end systolic diameter, LVEDV,
LVESD and LVEF, obtained according to Simpson’s
rule.
Myocardial contrast echocardiography
Myocardial contrast echocardiography will be performed
in both groups immediately before the first dose of
Lenograstim or placebo and on the morning of the last
day of treatment. Myocardial contrast echocardiography
will be carried out by using a new generation echo
machine (iE33, Philips, Milan, Italy), equipped with a
3.5-MHz ultrasound probe and contrast pulse sequen-
cing, which is a software for acquisition and analysis of
contrast signal. Analysis of contrast signal relies on a
continuous emission of ultrasound and a contemporary
comparison between fundamental harmonics deriving
from tissues and second harmonics reflected by micro-
bubbles. When using this kind of imaging modality, the
image will normally be totally dark prior to contrast
administration, as the signal coming from the tissues is
nullified and suppressed, whereas the microbubbles’
signal is amplified. A second generation ultrasound con-
trast agent SonoVue® (Bracco, Milan, Italy) will be ad-
ministered, according to the market authorization, by
peripheral venous access and continuously injected by a
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dedicated infusion pump (VueJECT, Bracco, Milan,
Italy). Continuous infusion provides a constant bubble
signal that is fundamental to assess myocardial perfu-
sion. After the destruction of microbubbles by a high
mechanical index pulse, myocardial perfusion will be
visually assessed during their replenishment of the cor-
onary circulation Images will be acquired as follows:
real-time and triggered apical four-chamber view, real-
time and triggered apical two-chamber view, real-time
and triggered apical three-chamber view, real-time and
triggered parasternal short-axis view.
Duration of the study
Each enrolled patient will remain in the study throughout
the entire study duration, with a minimum follow-up of
1 year for each patient. A study patient’s participation may
be terminated early for reasonable cause, such as the in-
vestigator’s medical decision. At any time the patient has
the right to withdraw consent without a negative impact
on their medical treatment. However, the investigators are
encouraged to ask for the patient’s permission for further
follow-up telephone contacts from those whose decision
for discontinuation was based on the need for further out-
patient visits. Patients will be enrolled during a recruit-
ment phase of approximately 2 years. Since minimum
study duration for one patient is 1 year, the overall study
duration is approximately 3 years. The Data Monitoring
Committee may terminate the study earlier based on
safety concerns at any time, or based on the interim effi-
cacy analysis. Competent authorities/ethics committees
retain the right of premature termination of the study
according to applicable regulations. At an individual
study center, the study may be terminated early if the
work performed is not compliant with Good Clinical
Practice guidelines.
Statistical methods
The sample size was calculated on the basis of our previ-
ous experience, assuming a difference in LVEF of 5 %
between the group treated with G-CSF and controls and
a standard deviation of 7 %. In addition, considering the
novelty of the study one interim analysis will be per-
formed after the enrollment of 60 patients to check
presence of a favorable effect of G-CSF +MCE on left
ventricular function in comparison to placebo +MCE.
Early termination will be possible at this stage if the ex-
perimental group show no increase in LVEF fraction in
comparison to the control group. However, all patients
recruited must complete a 1-year follow-up, even if the
trial is stopped prematurely.
All collected data will be summarized by treatment
group. Continuous data will be reported by the number
of available data points, mean, standard deviation, me-
dian and interquartile range. Categorical and ordinal
data will be summarized by observed frequencies and
percentages relative to the number of non-missing
data. For continuous data, comparisons between treat-
ment groups will be done using a two-sample t test,
or a Wilcoxon rank-sum test if data show serious de-
viations from a normal distribution. Categorical data
will be compared using a chi-square test or Fisher’s
exact test, as appropriate. Ordinal data will be com-
pared using a chi-square test for trend.
The primary endpoint of all-cause mortality will be the
change in LVEF evaluated by cardiac magnetic reson-
ance. Statistical significance will be claimed when the
resulting p value is lower than 0.05.
Adverse events, related adverse events and severe ad-
verse events will be summarized by body system and
preferred term for the two treatment groups.
Discussion
In the last two decades, several clinical trials have inves-
tigated the effects of G-CSF therapy on cardiac repair:
the results collected so far, however, indicate that G-CSF
therapy is safe and may be associated with beneficial ef-
fects in patients with large AMI. However, the limited
amount of evidence is inadequate to reach any definitive
conclusions regarding the efficacy of G-CSF therapy.
Therefore, larger randomized clinical trials, with ap-
propriate power calculations, are needed in order to
address the current uncertainties regarding this ex-
perimental therapeutic approach.
The RIGENERA 2.0 trial, presented here, will test the
combined efficacy of G-CSF administration and MCE
in improving the regional and global left ventricular
contractile function and reducing infarct extension in
patients with large AMI, through the homing enhance-
ment of the bone marrow-derived cells within the myo-
cardium. The results of the present study are expected
to envision the routine clinical use of this safe, affordable
and reproducible approach in AMI patients with left ven-
tricular dysfunction after successful revascularization.
Trial status
The RIGENERA 2.0 trial received ethical committee
approval (Comitato Etico del Policlinico Gemelli, Roma)
and AIFA (Agenzia Italiana del Farmaco) approval in
July 2015 and has not yet begun patient recruitment.
Additional file
Additional file 1: Procedure schedule and description of study
assessments. Description of data: in this file a detailed description of the
study assessments and their schedule is provided. (PDF 224 kb)
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